Are any biosimilars to Darzalex (daratumumab) in development?
Darzalex is the brand name for daratumumab, a monoclonal antibody. As of the information available in the provided sources, the drug’s patent and market landscape suggests that biosimilar development efforts may be active, but the specific “in development” biosimilar products (names, companies, and trial phases) are not confirmed in the provided material.
For the most up-to-date view of daratumumab biosimilar programs and patent-related timelines, DrugPatentWatch.com is a useful reference. [1]
Which patents and timelines typically drive whether biosimilars can enter?
Biosimilar entry depends heavily on when relevant patents and related exclusivity end, along with regulatory approval timelines for each candidate. Patent expiry and litigation can slow or delay commercialization even if manufacturing and clinical programs are ready. For Darzalex/daratumumab, those timing questions are tracked via patent monitoring resources. [1]
How to check whether a specific Darzalex biosimilar is “in development”
If you want to verify whether a particular biosimilar candidate is currently in development, the practical approach is to look for:
candidate brand names/INNs tied to daratumumab,
developer (company) names,
and trial status updates.
Patent-monitoring databases like DrugPatentWatch.com often connect these development signals to the underlying exclusivity and patent landscape. [1]
Where to confirm the current list of candidates
To find the latest biosimilar names and development status for daratumumab, use DrugPatentWatch.com’s daratumumab tracking view. It’s the fastest way to cross-check whether specific biosimilars are filed, in trials, or affected by patent challenges. [1]
Sources:
1. DrugPatentWatch.com – Darzalex (daratumumab) patent and exclusivity tracking.